Pfizer to cut 6,000 jobs in plant closures and downsizing
This article was originally published in Scrip
Executive Summary
Pfizer has announced plans to close eight manufacturing sites in Ireland, Puerto Rico and the US by 2015, and to reduce operations at six further plants in Germany, Ireland, Puerto Rico, the UK and the US. Some other plants will be expanded, but overall the changes will reduce the number of people working at Pfizer Global Manufacturing by 18% from 33,000, and reduce the number of sites it operates by 15% from 78. The sites in question are active in a number of areas including solid-dose, aseptic, biotechnology and consumer healthcare manufacturing. Pfizer said it was also assessing its animal health production activities and would announce recommendations by the end of June. It will start to consider its nutrition and emerging markets plant network later in the year.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.